Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Meletios Α. Dimopoulos, Vânia Hungria, Atanas Radinoff, Sosana Delimpasi, Gábor Mikala, Tamás Masszi, Li J, Marcelo Capra, Ângelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Löw, Morio Matsumoto, Neal Sule, Mary Li, Astrid McKeown, Wei He, Shelley Bright, Brooke M. Currie, Sue Perera, Julia Boyle, Sumita Roy–Ghanta, Joanna Opalińska, Katja Weisel